Pharmacological management of autoimmune hepatitis

Expert Opinion on Pharmacotherapy

Volumn 12, Issue 4, 2011, Pages 607-613

  Vergani, Diego ^a   Mieli Vergani, Giorgina ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

Autoimmune hepatitis; Azathioprine; Corticosteroids; Regulatory T cells

Indexed keywords

6 METHYLTHIOINOSINE; AZATHIOPRINE; BUDESONIDE; CYCLOSPORIN A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; PREDNISONE; TACROLIMUS; TIOGUANINE; URSODEOXYCHOLIC ACID;

AUTOIMMUNE HEPATITIS; BONE MARROW SUPPRESSION; CATARACT; CHOLESTATIC HEPATITIS; CUSHING DISEASE; DIABETES MELLITUS; DIARRHEA; DIZZINESS; DRUG BLOOD LEVEL; DRUG COST; DRUG DOSE INCREASE; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG METABOLISM; GINGIVA HYPERPLASIA; HAIR LOSS; HUMAN; HYPERTENSION; HYPERTRICHOSIS; LIVER FUNCTION TEST; LIVER TRANSPLANTATION; LOW DRUG DOSE; NAUSEA; NEUTROPENIA; NONHUMAN; OSTEOPOROSIS; PANCREATITIS; PROGNOSIS; PSYCHOSIS; RELAPSE; REMISSION; REVIEW; SIDE EFFECT; SPINE DISEASE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VEIN OCCLUSION; VERTEBRA COLLAPSE; VOMITING;

ADULT; AZATHIOPRINE; CHILD; DISEASE PROGRESSION; END STAGE LIVER DISEASE; HEPATITIS, AUTOIMMUNE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; PREDNISOLONE; TIME FACTORS; TREATMENT OUTCOME;

EID: 79951604117     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2011.524206     Document Type: Review

References (54)

1. Krawitt EL. Autoimmune hepatitis. N Engl J Med 2006;354(1):54-66 (Pubitemid 43048951)
2. Manns MP, Czaja AJ, Gorham JD, et al. Diagnosis and management of autoimmune hepatitis. Hepatology 2010;51(6):2193-213
3. Kirk AP, Jain S, Pocock S, et al. Late results of the Royal Free Hospital prospective controlled trial of prednisolone therapy in hepatitis B surface antigen negative chronic active hepatitis. Gut 1980;21(1):78-83 (Pubitemid 10157086)
4. Gregorio GV, Portmann B, Reid F, et al. Autoimmune hepatitis in childhood: a 20-year experience. Hepatology 1997;25(3):541-7 (Pubitemid 27106430)
5. Vergani D, Mieli-Vergani G. Autoimmune hepatitis. Textbook of Hepatology: from Basic Science to Clinical Practice. 3rd edition. Blackwell Publishing, UK; 2007. p. 1089-101
6. Alvarez F, Berg PA, Bianchi FB, et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999;31(5):929-38 (Pubitemid 29514229)
7. Hennes EM, Zeniya M, Czaja AJ, et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology 2008;48(1):169-76 (Pubitemid 351975541)
8. Seela S, Sheela H, Boyer JL. Autoimmune hepatitis type 1: safety and efficacy of prolonged medical therapy. Liver Int 2005;25(4):734-9 (Pubitemid 41038654)
9. Sogo T, Fujisawa T, Inui A, et al. Intravenous methylprednisolone pulse therapy for children with autoimmune hepatitis. Hepatol Res 2006;34(3):187-92
10. Ustundag G, Kuloglu Z, Kirsaclioglu CT, et al. Complete regression of cirrhosis after immunosuppressive treatment in autoimmune hepatitis. Pediatr Int 2008;50(5):711-13
11. Kerkar N, Annunziato RA, Foley L, et al. Prospective analysis of nonadherence in autoimmune hepatitis: a common problem. J Pediatr Gastroenterol Nutr 2006;43(5):629-34 (Pubitemid 44863690)
12. Samaroo B, Samyn M, Buchanan C, Mieli-Vergani G. Long-term daily oral treatment with prednisolone in children with autoimmune liver disease does not affect final adult height. Hepatology 2006;44:438A
13. Johnson PJ, McFarlane IG, Williams R. Azathioprine for long-term maintenance of remission in autoimmune hepatitis [see comments]. N Engl J Med 1995;333(15):958-63
14. Czaja AJ, Freese DK. Diagnosis and treatment of autoimmune hepatitis. Hepatology 2002;36(2):479-97 (Pubitemid 34810370)
15. Heneghan MA, Norris SM, O'Grady JG, et al. Management and outcome of pregnancy in autoimmune hepatitis. Gut 2001;48(1):97-102 (Pubitemid 32042648)
16. Candia L, Marquez J, Espinoza LR. Autoimmune hepatitis and pregnancy: a rheumatologist's dilemma. Semin Arthritis Rheum 2005;35(1):49-56 (Pubitemid 41111471)
17. Terrabuio DR, Abrantes-Lemos CP, Carrilho FJ, Cancado EL. Follow-up of pregnant women with autoimmune hepatitis: the disease behavior along with maternal and fetal outcomes. J Clin Gastroenterol 2009;43(4):350-6
18. Al-Chalabi T, Boccato S, Portmann BC, et al. Autoimmune hepatitis (AIH) in the elderly: a systematic retrospective analysis of a large group of consecutive patients with definite AIH followed at a tertiary referral centre. J Hepatol 2006;45(4):575-83 (Pubitemid 44307378)
19. Lennard L, Van Loon JA, Weinshilboum RM. Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism. Clin Pharmacol Ther 1989;46(2):149-54 (Pubitemid 19219950)
20. Ben Ari Z, Mehta A, Lennard L, Burroughs AK. Azathioprine-induced myelosuppression due to thiopurine methyltransferase deficiency in a patient with autoimmune hepatitis. J Hepatol 1995;23(3):351-4
21. Gisbert JP, Gomollon F, Cara C, et al. Thiopurine methyltransferase activity in Spain: a study of 14,545 patients. Dig Dis Sci 2007;52(5):1262-9 (Pubitemid 46626159)
22. Kaskas BA, Louis E, Hindorf U, et al. Safe treatment of thiopurine S-methyltransferase deficient Crohn's disease patients with azathioprine. Gut 2003;52(1):140-2 (Pubitemid 36020781)
23. Czaja AJ, Carpenter HA. Thiopurine methyltransferase deficiency and azathioprine intolerance in autoimmune hepatitis. Dig Dis Sci 2006;51(5):968-75 (Pubitemid 44030824)
24. Cuffari C, Dassopoulos T, Turnbough L, et al. Thiopurine methyltransferase activity influences clinical response to azathioprine in inflammatory bowel disease. Clin Gastroenterol Hepatol 2004;2(5):410-17 (Pubitemid 38561239)
25. Czaja AJ. Safety issues in the management of autoimmune hepatitis. Expert Opin Drug Saf 2008;7(3):319-33 (Pubitemid 351802831)
26. Wang KK, Czaja AJ, Beaver SJ, Go VL. Extrahepatic malignancy following long-term immunosuppressive therapy of severe hepatitis B surface antigen-negative chronic active hepatitis. Hepatology 1989;10(1):39-43 (Pubitemid 19170001)
27. Werner M, Almer S, Prytz H, et al. Hepatic and extrahepatic malignancies in autoimmune hepatitis. A long-term follow-up in 473 Swedish patients. J Hepatol 2009;50(2):388-93
28. Yeoman AD, Al-Chalabi AT, Karani JB, et al. Evaluation of risk factors in the development of HCC in AIH: Implications for follow-up and screening. Hepatology 2008;48:863-70
29. Chang MH, Hadzic D, Rouassant SH, et al. Acute and chronic hepatitis: working group report of the second World congress of pediatric gastroenterology, hepatology, and nutrition. J Pediatr Gastroenterol Nutr 2004;39(Suppl 2):S584-8
30. Rumbo C, Emerick KM, Emre S, Shneider BL. Azathioprine metabolite measurements in the treatment of autoimmune hepatitis in pediatric patients: a preliminary report. J Pediatr Gastroenterol Nutr 2002;35(3):391-8
31. Dumortier J, Arita CT, Rivet C, et al. Long-term treatment reduction and steroids withdrawal in children with autoimmune hepatitis: a single centre experience on 55 children. Eur J Gastroenterol Hepatol 2009;21(12):1413-18
32. Banerjee S, Rahhal R, Bishop WP. Azathioprine monotherapy for maintenance of remission in pediatric patients with autoimmune hepatitis. J Pediatr Gastroenterol Nutr 2006;43(3):353-6 (Pubitemid 44368192)
33. Cuarterolo M, Ciocca M, Velasco CC, et al. Follow-up of children with autoimmune hepatitis treated with cyclosporine. J Pediatr Gastroenterol Nutr 2006;43(5):635-9 (Pubitemid 44863691)
34. Alvarez F, Ciocca M, Canero-Velasco C, et al. Short-term cyclosporine induces a remission of autoimmune hepatitis in children. J Hepatol 1999;30:222-7 (Pubitemid 29071183)
35. Debray D, Maggiore G, Girardet JP, et al. Efficacy of cyclosporin A in children with type 2 autoimmune hepatitis. J Pediatr 1999;135(1):111-14 (Pubitemid 30180574)
36. Van Thiel DH, Carroll P, Abu-Elmagd K, et al. Tacrolimus (FK 506), a treatment for primary sclerosing cholangitis: results of an open-label preliminary trial. Am J Gastroenterol 1995;90(3):455-9
37. Aqel BA, Machicao V, Rosser B, et al. Efficacy of tacrolimus in the treatment of steroid refractory autoimmune hepatitis. J Clin Gastroenterol 2004;38(9):805-9 (Pubitemid 39274185)
38. Larsen FS, Vainer B, Eefsen M, et al. Low-dose tacrolimus ameliorates liver inflammation and fibrosis in steroid refractory autoimmune hepatitis. World J Gastroenterol 2007;13(23):3232-6 (Pubitemid 47064587)
39. Gao E, Lo D, Cheney R, et al. Abnormal differentiation of thymocytes in mice treated with cyclosporin A. Nature 1988;336:176-9 (Pubitemid 18266146)
40. Bucy PB, Yan Xu X, Li J, Huang GQ. Cyclosporin A-induced autoimmune disease in mice. J Immunol 1993;151:1039-50 (Pubitemid 23215769)
41. Wu DY, Goldschneider I. Cyclosporin A-induced autologous graft-versus-host disease: a prototypical model of autoimmunity and active (dominant) tolerance coordinately induced by recent thymic emigrants. J Immunol 1999;162(11):6926-33 (Pubitemid 29309422)
42. Damoiseaux JG, van Breda Vriesman PJ. Cyclosporin A-induced autoimmunity: the result of defective de novo T- cell development. Folia Biol 1998;44(1):1-9 (Pubitemid 28048332)
43. Mieli-Vergani G, Vergani D. De novo autoimmune hepatitis after liver transplantation. J Hepatol 2004;40(1):3-7 (Pubitemid 38064706)
44. Wiegand J, Schuler A, Kanzler S, et al. Budesonide in previously untreated autoimmune hepatitis. Liver Int 2005;25(5):927-34 (Pubitemid 41404011)
45. Czaja AJ, Carpenter HA, Lindor KD. Ursodeoxycholic acid as adjunctive therapy for problematic type 1 autoimmune hepatitis: a randomized placebo-controlled treatment trial. Hepatology 1999;30(6):1381-6
46. Manns MP, Woynarowski M, Kreisel W, et al. Azathioprine with budesonide induces remission more effectively than with prednisone in patients with autoimmune hepatitis. Gastroenterology 2010;139:1198-206
47. Aw MM, Dhawan A, Samyn M, et al. Mycophenolate mofetil as rescue treatment for autoimmune liver disease in children: a 5-year follow-up. J Hepatol 2009;51(1):156-60
48. Richardson PD, James PD, Ryder SD. Mycophenolate mofetil for maintenance of remission in autoimmune hepatitis in patients resistant to or intolerant of azathioprine. J Hepatol 2000;33(3):371-5 (Pubitemid 30663373)
49. Gregorio GV, McFarlane B, Bracken P, et al. Organ and non-organ specific autoantibody titres and IgG levels as markers of disease activity: a longitudinal study in childhood autoimmune liver disease. Autoimmunity 2002;35(8):515-19 (Pubitemid 36321892)
50. Luth S, Herkel J, Kanzler S, et al. Serologic markers compared with liver biopsy for monitoring disease activity in autoimmune hepatitis. J Clin Gastroenterol 2008;42(8):926-30
51. Duclos-Vallee JC, Sebagh M, Rifai K, et al. A 10 year follow up study of patients transplanted for autoimmune hepatitis: histological recurrence precedes clinical and biochemical recurrence. Gut 2003;52(6):893-7 (Pubitemid 36613499)
52. Kerkar N, Dugan C, Rumbo C, et al. Rapamycin successfully treats post-transplant autoimmune hepatitis. Am J Transplant 2005;5(5):1085-9 (Pubitemid 40571258)
53. Lobo-Yeo A, Alviggi L, Mieli-Vergani G, et al. Preferential activation of helper/ inducer T lymphocytes in autoimmune chronic active hepatitis. Clin Exp Immunol 1987;67(1):95-104 (Pubitemid 17222166)
54. Longhi MS, Ma Y, Mieli-Vergani G, Vergani D. Aetiopathogenesis of autoimmune hepatitis. J Autoimmun 2010;34(1):7-14